TAFSURE (Tenofovir & Alafenamide) is a generic version of tenofovir alafenamide (TAF) for the treatment of chronic hepatitis B in adults.
The drug TAFSURE (Tenofovir & Alafenamide) is a real breakthrough in the treatment of viral hepatitis B, since the patient needs to consume less of the drug while achieving a higher treatment effect. The efficacy and safety of tenofovir alafenamide in the treatment of viral hepatitis B has been shown in clinical trials among treated and non-treated patients. In both clinical trials, the primary endpoints of the study were successfully achieved, which consisted of reducing the level of hepatitis B virus DNA to 29 IU / ml.
Tenofovir alafenamide is a prodrug of tenofovir. The mechanism of action of tenofovir alafenamide is similar to that of tenofovir, however, comparable antiviral activity of tenofovir alafenamide is observed with the introduction of 10 times lower doses. Tenofovir alafenamib has also been shown to have less adverse effects on bone mineral density than tenofovir.
Indications for Use
TAFSURE is a prescription drug used to treat chronic hepatitis B virus (HBV) in adults with a stable course in the compensatory phase. The drug is designed to reduce the amount of hepatitis B virus in the body, as well as improve the patient’s liver.